Thyroid cancer - medullary carcinomaThyroid - medullary carcinoma; Cancer - thyroid (medullary carcinoma); MTC; Thyroid nodule - medullary
Medullary carcinoma of the thyroid is cancer of the thyroid gland that starts in cells that release a hormone called calcitonin. These cells are called "C" cells. The thyroid gland is located inside the front of your lower neck.
The cause of medullary carcinoma of the thyroid (MTC) is unknown. MTC is very rare. It can occur in children and adults.
Unlike other types of thyroid cancer, MTC is less likely to be caused by radiation therapy to the neck given to treat other cancers during childhood.
There are two forms of MTC:
- Sporadic MTC, which does not run in families. Most MTCs are sporadic. This form mainly affects older adults.
- Inherited MTC, which runs in families.
You have an increased risk for this type of cancer if you have:
- A family history of MTC
- A family history of multiple endocrine neoplasia (MEN)
- Had prior history of pheochromocytoma, mucosal neuromas, hyperparathyroidism or pancreatic endocrine tumors
Other types of thyroid cancer include:
- Anaplastic carcinoma of the thyroid
- Follicular tumor of the thyroid
- Papillary carcinoma of the thyroid
- Thyroid lymphoma
MTC often begins as a small lump (nodule) in the thyroid gland. There may also be lymph node swelling in the neck. As a result, symptoms may include:
- Swelling of the neck
- Breathing problems due to narrowing of airways
- Cough with blood
- Diarrhea due to high calcitonin level
Exams and Tests
Your health care provider will perform a physical exam and ask about your symptoms and medical history.
Tests that may be used to diagnose MTC include:
- Calcitonin blood test
- CEA blood test
- Genetic testing
- Thyroid biopsy
- Ultrasound of the thyroid
- PET scan
People with MTC should be checked for certain other tumors, especially pheochromocytoma.
Treatment involves surgery to remove the thyroid gland and surrounding lymph nodes. Because this is an uncommon tumor, surgery should be performed by a surgeon who is familiar with this type of cancer and experienced with the operation required.
Chemotherapy and radiation do not work very well for this type of cancer. Radiation is used in some people after surgery. New treatments are being investigated in clinical trials. Your provider can tell you more about these, if needed.
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you not feel alone.
People with medullary carcinoma of the thyroid live at least 5 years after diagnosis, depending upon the stage of the cancer. Women have better prognosis than men. The 10 year survival rate is 75%.
Complications may include:
- Cancer spreads to other areas of the body
- Parathyroid glands are accidentally removed during surgery
When to Contact a Medical Professional
Call your provider if you have symptoms of medullary carcinoma of the thyroid.
Prevention may not be possible. But, being aware of your risk factors, especially your family history, may allow for early diagnosis and treatment. For people who have a very strong family history of MTC, the option to remove the thyroid gland may be recommended. You should carefully discuss this option with a doctor who is very familiar with the disease.
National Cancer Institute website. Thyroid cancer treatment (adult) (PDQ) - health professional version. www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq. Updated February 1, 2018. Accessed March 22, 2018.
Smith PW, Hanks LR, Salomone LJ, Hanks JB. Thyroid. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery. 20th ed. Philadelphia, PA: Elsevier Saunders; 2017:chap 36.
Wells SA. Medullary thyroid carcinoma. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 246.
Review Date: 1/19/2018
Reviewed By: Richard LoCicero, MD, private practice specializing in hematology and medical oncology, Longstreet Cancer Center, Gainesville, GA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.